Original language | English (US) |
---|---|
Pages (from-to) | 443-454 |
Number of pages | 12 |
Journal | Clinical and Translational Science |
Volume | 10 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2017 |
ASJC Scopus subject areas
- Neuroscience(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Precision Dosing : Public Health Need, Proposed Framework, and Anticipated Impact. / Gonzalez, Daniel; Rao, Gauri G.; Bailey, Stacy C.; Brouwer, Kim L.R.; Cao, Yanguang; Crona, Daniel J.; Kashuba, Angela D.M.; Lee, Craig R.; Morbitzer, Kathryn; Patterson, J. Herbert; Wiltshire, Tim; Easter, Jon; Savage, Scott W.; Powell, J. Robert.
In: Clinical and Translational Science, Vol. 10, No. 6, 11.2017, p. 443-454.Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Precision Dosing
T2 - Public Health Need, Proposed Framework, and Anticipated Impact
AU - Gonzalez, Daniel
AU - Rao, Gauri G.
AU - Bailey, Stacy C.
AU - Brouwer, Kim L.R.
AU - Cao, Yanguang
AU - Crona, Daniel J.
AU - Kashuba, Angela D.M.
AU - Lee, Craig R.
AU - Morbitzer, Kathryn
AU - Patterson, J. Herbert
AU - Wiltshire, Tim
AU - Easter, Jon
AU - Savage, Scott W.
AU - Powell, J. Robert
N1 - Funding Information: research from the National Institute of Child Health and Human Development (K23HD083465), the nonprofit organization Thrasher Research Fund (www.thrasherresearch.org), and from industry (Cempra, Inc. and Jacobus Pharmaceutical Company, Inc.) for drug development in adults and children. S.C.B. has served as a consultant to Merck, Sharp and Dohme and to Luto (UK). She has received funding via her institution from Merck, Sharp and Dohme, Eli Lilly Company, AHRQ, and the National Institutes of Health for studies that use the electronic health record to improve prescribing and patient monitoring. Y.C. recieves support from the National Institute of General Medical Sciences (GM119661). K.L.R.B. receives support from the National Institute of General Medical Sciences through award numbers R01GM041935 and R35GM122576, and from industry (Otsuka Pharmaceutical Development and Commercialization, Inc., and Intercept Pharmaceuticals). K.L.R.B. is a coinventor of the sandwich-cultured hepatocyte technology for quantification of biliary excretion (B-CLEAR) and related technologies, which have been licensed exclusively to Qualyst Transporter Solutions, LLC. A.D.M.K. receives support for research from the National Institute of Allergy and Infectious Diseases (R01AI122319, R01AI111891, P30AI050410, R01AI116276, R01AI117739, U01AI103390, UM1AI126619), the National Center for Advancing Translational Sciences (UL1TR001111), the National Institute of Child Health and Human Development (K12HD001441), and from industry (Gilead, Merck) for clinical pharmacology and drug development. C.R.L. receives research support from the American Heart Association (16GRNT29300003). J.R.P. has served as paid consultant to Takeda, AbbVie, and Hengrui Pharmaceuticals over the past year. The remaining authors have no conflicts to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
PY - 2017/11
Y1 - 2017/11
UR - http://www.scopus.com/inward/record.url?scp=85032922602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032922602&partnerID=8YFLogxK
U2 - 10.1111/cts.12490
DO - 10.1111/cts.12490
M3 - Review article
C2 - 28875519
AN - SCOPUS:85032922602
VL - 10
SP - 443
EP - 454
JO - Clinical and Translational Science
JF - Clinical and Translational Science
SN - 1752-8054
IS - 6
ER -